lacosamide adroiq
extrovis eu ltd. - lakosamid - epilepsie - antiepileptika, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
lacosamide accord
accord healthcare s.l.u. - lakosamid - epilepsie - antiepileptika, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy• in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastická činidla - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
zonisamide mylan
mylan pharmaceuticals limited - zonisamid - epilepsie - antiepileptika, - monoterapie při léčbě parciálních záchvatů s nebo bez sekundární generalizace u dospělých s nově diagnostikovanou epilepsií;přídatná terapie při léčbě parciálních záchvatů s nebo bez sekundární generalizace u dospělých, dospívajících a dětí ve věku 6 let a výše.
meloxicam bioveta 1,5 mg/ml perorální suspenze
bioveta, a.s. - meloxikam - perorální suspenze - oxicams - psi
lacosamide ucb
ucb pharma s.a. - lakosamid - epilepsie, částečné - antiepileptika, - lacosamid ucb je indikován jako monoterapie a přídatná terapie při léčbě parciálních záchvatů s nebo bez sekundární generalizace u dospělých, dospívajících a dětí od 4 let věku s epilepsií.
lacosamide glenmark 100mg potahovaná tableta
glenmark pharmaceuticals s.r.o., praha array - 16489 lakosamid - potahovaná tableta - 100mg - lakosamid
lacosamide glenmark 150mg potahovaná tableta
glenmark pharmaceuticals s.r.o., praha array - 16489 lakosamid - potahovaná tableta - 150mg - lakosamid
lacosamide glenmark 200mg potahovaná tableta
glenmark pharmaceuticals s.r.o., praha array - 16489 lakosamid - potahovaná tableta - 200mg - lakosamid
lacosamide glenmark 50mg potahovaná tableta
glenmark pharmaceuticals s.r.o., praha array - 16489 lakosamid - potahovaná tableta - 50mg - lakosamid